Thrombosis is a frequent complication of polycythemia vera and essential thrombocythemia, but its incidence and predisposing factors in idiopathic myelofibrosis (IM) are unknown. In 18 (11.6%) of 155 patients diagnosed with IM in a single institution, 31 thrombotic events (19 arterial, 12 venous) were registered after a mean follow-up of 4.2 (s.d.: 4.5) years. In six patients, the thrombosis was simultaneous to or appeared a few months before IM diagnosis and 14 had one or more thrombotic episodes. When compared with the general population, a significant increase was observed in the incidence of venous thrombosis (odds ratio 17.5, 95% confidence interval: 10.3-31.4). At multivariate analysis, the initial variables associated with an increased risk of thrombosis were thrombocytosis (platelets 4450 Â 10 9 /l, P ¼ 0.001), presence of one cardiovascular risk factor (arterial hypertension, smoking, hypercholesterolemia, or diabetes, P ¼ 0.003), cellular phase of myelofibrosis (P ¼ 0.005), and Hb 411 g/dl (P ¼ 0.02). Considering post-diagnosis events, the 5-year thrombosis-free survival probability was 90.4% in the series, 80.6% for patients with platelets 4450 Â 10 9 /l, 82.6% for patients with one cardiovascular risk factor, and 85.1% for those in cellular phase. These results indicate an increased thrombotic risk for IM patients with hyperproliferative features and/or coexistent cardiovascular risk factors.
Introduction
The classical Ph-negative chronic myeloproliferative disorders (MPDs) are a group of heterogeneous diseases of clonal origin arising in a pluripotent hemopoietic stem cell, which includes polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IM). From the clinical point of view, two of them, PV and ET, are associated with an increased frequency of thrombosis, with this complication representing the main cause of morbidity and mortality in both diseases. Thus, more than 40% of PV patients develop thrombotic complications prior to diagnosis, at presentation or during their evolution, 1,2 and the proportion is up to 30% in ET patients. [3] [4] [5] With regard to IM, the most infrequent of the MPDs and the one with a poorer prognosis, there have been isolated reports of small series of patients, suggesting an increased occurrence of thrombosis, 6, 7 whereas an excess of thrombotic events has also been registered in these patients following splenectomy. [8] [9] [10] [11] However, no information is available on the overall frequency of thrombosis in IM and, therefore, it is not known whether patients with this disease actually have an increased tendency to develop such complication.
The primary aim of the present study was to determine the frequency and type of thrombosis in IM patients and the possible factors associated with the appearance of this complication. For this purpose, 155 patients consecutively diagnosed with IM and followed up at the same institution during their whole clinical course were analyzed.
Patients and methods

Patient population and diagnostic criteria
Between 1972 and 2005, 163 patients were consecutively diagnosed with IM at the Hematology Department of the Hospital Clínic of Barcelona, Spain. In eight of them, information on the follow-up was incomplete, since they had been mostly controlled in other hospitals after the initial diagnosis. The analysis was therefore restricted to the 155 patients who were followed up at our institution along their whole clinical course. In order to avoid possible biases, patients with postpolycythemic 12 or post-thrombocythemic myelofibrosis 13 were not considered. The same applied to patients with the so-called 'pre-fibrotic' form of myelofibrosis.
14 The diagnosis of IM was based on the criteria established by the Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. 15 Bone marrow histology was evaluated according to the criteria by Lennert et al, 16 in which three myelofibrosis subtypes are considered: cellular or MF/C phase (myelofibrosis with increased hemopoietic cellularity and reticulin fibrosis), MF/OÀ phase (myelofibrosis with reticulin and collagen fibrosis but no new bone formation), and osteosclerotic or MF/O þ phase (decreased hemopoietic cellularity, marked reticulin and collagen fibrosis, and osteosclerosis). The karyotype of bone marrow or unstimulated peripheral blood cells was analyzed whenever assessable metaphases could be obtained.
Treatment
Treatment was heterogeneous, with the therapeutic choice being primarily based on the patients' age and clinicohematological characteristics. It consisted of either a wait-and-see approach or supportive therapy exclusively in 46 patients. The remaining 109 patients received one or more of the following therapies: hydroxyurea (44 cases), androgens (36 cases: danazol, n ¼ 33; oxymetholone, n ¼ 3), erythropoietin (20 patients), prednisone (15 patients), 6-mercaptopurine (10 patients), anagrelide (five patients), interferon alpha (five patients), busulfan (four patients), 1,25-dihydroxy-vitamin D (two patients), and 32 P, cyclophosphamide, and cyclosporin A (one patient each). As a rule, platelet-lowering agents (mostly hydroxyurea) were administered to patients with thrombocytosis. In all, 21 patients underwent splenectomy, usually because of massive symptomatic splenomegaly or refractory anemia, and three received splenic irradiation. Allogeneic stem cell transplantation was performed in four patients.
Vascular complications
For the purpose of the present study, only major vascular events, defined according to the International Classification of Diseases (Ninth Revision), were considered. Arterial thromboses included: stroke, transient ischemic attacks (TIA), retinal artery occlusion, coronary arterial disease (angina pectoris or myocardial infarction), and peripheral arterial disease (intermittent claudication and thromboembolism of the leg arteries). Venous thromboses included: cerebral venous sinus thrombosis, deepvein thrombosis, pulmonary thromboembolism, Budd-Chiari syndrome (BCS), and portal vein thrombosis (PVT). Minor occlusive events, such as erythromelalgia and superficial thrombophlebitis of the extremities, were not included in the analysis. Acute myocardial infarction was defined by at least two of the following findings: chest pain of typical intensity and duration, ST-segment elevation or depression X1 mm in any limb lead on electrocardiography, X2 mm in any precordial lead or both, and at least doubling of the serum levels of the cardiac enzymes. Peripheral artery disease was diagnosed by angiography. Diagnosis of stroke required signs or symptoms of a neurologic deficit with sudden onset and a duration of more than 24 h, and it was confirmed by computed tomography (CT) since 1983 or magnetic resonance imaging since 1993. A TIA was defined as the abrupt onset of unilateral motor or sensory disturbances, speech defects, homonymous hemianopsia, constructional apraxia, or transient monocular blindness that resolved completely in less than 24 h. Pulmonary embolism was diagnosed by a positive angiogram or ventilation-perfusion scan or a CT scan indicating a high probability of such complication. Deep venous thrombosis was diagnosed by phlebography or doppler ultrasonography. BCS was defined as a hepatic venous outflow obstruction at any level from the small hepatic veins to the junction of the inferior vena cava and the right atrium, and PVT as the presence of endoluminal material with absence of flow in the portal vein access or cavernous transformation of the vein. Both BCS and PVT were documented by doppler ultrasonography and hemodynamic study.
Statistical methods
In each patient, the major thrombotic events occurring within the year preceding diagnosis of IM, at disease presentation or after diagnosis (and, in these cases, the time lapse between diagnosis and the vascular event), were recorded. In order to compare the rate of major thrombotic events in the series with the one in the general population, patients were distributed by age groups according to the distribution employed in the studies that were used for the comparison, which included peripheral arterial disease, 17 stroke, 18 venous thrombosis, 19 and coronary heart disease. 20 For each comparison, a ratio of the observed to the expected incidence of thrombotic events [17] [18] [19] [20] and a 95% confidence interval (CI) was calculated assuming a Poisson distribution. The following initial variables were analyzed for their possible association with the occurrence of thrombosis: age, gender, previous history of thrombosis, presence of vascular risk factors (arterial hypertension, current cigarette smoking, hypercholesterolemia, and diabetes mellitus), assessed as previously described, 4 spleen size, platelet count, Hb level, WBC count, absolute neutrophil and monocyte counts, serum levels of cholesterol, LDH and acid uric, and histologic phase of myelofibrosis in the bone marrow biopsy. Two evolutive variables (namely, splenectomy and cytolytic treatment) were also assessed for their influence on the occurrence of thrombosis. The t-test, the Mann-Whitney U-test and the w 2 test were employed to select the significant factors at the univariate level. Subsequently, in order to identify the independent predictors of thrombosis, these factors were included in a multivariate logistic regression analysis. Three variables previously described as having a possible influence on the appearance of thrombosis (i.e., age, sex, and previous splenectomy), and that were not selected as independent predictors, were individually forced into the final model, and relevant changes in the regression coefficients of the independent predictors were excluded. The contribution of each significant variable to the risk of thrombosis was estimated by the adjusted odds ratio with its 95% CI. The thrombotic risk during follow-up was assessed with the Kaplan-Meier method, followed by the log-rank test. Variables attaining a significant level at the univariate analysis were included in a Cox proportional hazards model for assessing their independent association with thrombosis. Significance was considered for P-values o0.05. The statistical analysis was performed using the SPSS 10.0 package (SPSS, Chicago, IL, USA). Table 1 summarizes the main clinical and laboratory features of the 155 patients at IM presentation. Distribution of the cardiovascular risk factors was as follows: 42 patients were current smokers, 23 had arterial hypertension, 16 diabetes mellitus, and 12 serum cholesterol levels higher than 220 mg/dl. In all, 74 patients had one cardiovascular risk factor, 18 had two factors, and one had three factors. With regard to histological distribution, 65 cases (42.5%) were classified as corresponding to the cellular phase of myelofibrosis, 66 (43.1%) to the MF/OÀ phase, and 22 (14.4%) to the osteosclerotic phase. Out of the 83 patients with assessable metaphases, 20 (24%) showed clonal chromosomal abnormalities, the most frequent ones being del 20q (four cases), trisomy 8 (three cases), and del 13q and -11 (two cases each). Below coastal margin.
Results
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At the time of the analysis, 104 patients had died. The median survival for the series was 4.1 (95% CI: 2.9-5.3) years. When patients were distributed into two groups according to the diagnostic period (from 1972 to 1990 and from 1991 to 2005), median survival of the 65 patients in the first group was 4.1 years (95% CI: 3.1-6.8), versus 3.9 years (95% CI: 2.1-5.3) for the 90 patients in the second group, with the difference being not significant. After a mean follow-up of 4.2 (s.d.: 4.5) years, a total of 31 thrombotic events were registered in 18 patients (11.6% of the series). In six patients, the thrombosis occurred within the year prior to diagnosis (four cases) or at disease presentation (two cases). Five of them had high platelet counts. In all, 14 patients (two of whom had a previous history of thrombosis) developed one or more thrombotic episodes during their evolution. Table 2 shows the main clinicohematological data at the time of appearance of the first thrombotic complication in the 18 patients with thrombosis. Table 3 summarizes the type and number of thrombotic events. As can be seen, 19 thromboses were arterial and 12 venous. Of the four subgroups of thrombosis considered (i.e., venous thrombosis, stroke, peripheral arterial disease, and coronary heart disease), venous thrombosis was the most frequent one. With regard to the site of the thrombosis, the cerebrovascular and the peripheral arteries were the territories most frequently involved. In five patients the thrombosis represented the cause of death, including BCS (two patients), and PVT, stroke, and PTE (one case each).
When compared with data from the general population, IM patients showed a significant increase in the incidence of venous thromboses (odds ratio 17.5, 95% CI: 10.3-31.4). The incidence of stroke was also increased (odds ratio 5.7, 95% CI: 2.1-15.3), but no increase in coronary and peripheral arterial disease was noted.
As shown in Table 4 , at univariate analysis, five initial variables (i.e., thrombocytosis 4450 Â 10 9 /l, cellular phase of myelofibrosis, presence of any cardiovascular risk factor, Hb 411 g/dl, and cholesterol levels 4220 mg/dl) were associated with an increased incidence of thrombosis. When they were included in the multivariate analysis together with age, gender, and splenectomy, only thrombocytosis (platelet counts 4450 Â 10 9 /l), cellular phase, presence of any cardiovascular risk factor, and Hb 411 g/dl retained their predictive value for the occurrence of major vascular complications (Table 5) . Of the 21 patients submitted to splenectomy, three had thrombotic complications shortly after the procedure, including two with pulmonary thromboembolism and one with recurrent thromboses in several territories (BCS, portal vein, deep vein, and cavernous sinus thrombosis).
Considering only the thrombotic events that occurred after diagnosis of IM, thrombosis-free survival probability at 5 years was 90.4% for the overall series (Figure 1) . At univariate Table 2 Main clinicohematological data at the time of the first thrombotic event in 18 patients with IM analysis, the prognostic factors for the appearance of thrombosis were the presence of at least one cardiovascular risk factor (P ¼ 0.02), platelet counts 4450 Â 10 9 /l (P ¼ 0.03), and cellular phase of myelofibrosis (P ¼ 0.05). At 5 years of follow-up, probability of thrombosis-free survival was 80.6% for patients with platelet counts 4450 Â 10 9 /l (versus 96.2% for patients with platelets p450 Â 10 9 /l, Figure 2a ), 82.6% for patients with at least one cardiovascular risk factor (versus 96.9% for patients with no risk factor, Figure 2b) , and 85.1% for patients with the cellular phase of myelofibrosis (versus 94.2% for those with other histological phases, Figure 2c) . At multivariate analysis, only cellular phase (hazard ratio 4.8, 95% CI: 1.5-15.7, P ¼ 0.009) and presence of any cardiovascular risk factor (hazard ratio 6.9, 95% CI: 1.5-31.6, P ¼ 0.01) retained their prognostic value for the appearance of thrombosis.
Discussion
IM is a heterogeneous disease in terms of presentation and evolution. Thus, patients may present with high, normal, or low platelet counts, and the same applies to leukocyte counts, and they may remain asymptomatic for prolonged periods of time or to have constitutional symptoms or symptoms derived from the anemia and the splenomegaly. In turn, the spectrum of the causes of morbidity and mortality in IM is very wide, including bleeding, infection, acute transformation, portal hypertension, hepatic failure secondary to the liver myeloid metaplasia, hemosiderosis, and thrombosis. 21 This is in sharp contrast with the other two Ph-negative MPDs, PV and ET, which behave rather homogeneously at presentation and have thrombosis, by far, as the main cause of morbidity. 
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Nearly a half of PV patients and up to a third of patients with ET have thrombotic complications. [1] [2] [3] [4] [5] With regard to IM, information on the occurrence of thrombosis is scarce, with a few published studies, including a small number of patients. 6, 7 Besides, data on the incidence of thrombosis in IM patients submitted to splenectomy have been provided. [8] [9] [10] [11] Brodmann et al. 6 reported a rate of thromboembolic complications of 16.7% events per 100 patient years in a series of 26 patients with myelofibrosis. In another smaller study, 7 a higher prevalence of coronary artery disease was found in IM patients as compared with those with PV and ET. In the splenectomy series of 223 IM patients from the Mayo Clinic, 8 an increased rate of thrombosis was registered, with this complication being usually associated with the appearance of thrombocytosis following the procedure. 8 In another series of 26 IM splenectomized patients, 9 a 12% rate of venous thrombosis was observed. Finally, myelofibrosis was identified as a risk factor for the development of PVT after splenectomy in two studies. 10, 11 Some characteristics of the present study deserve comment. First, only IM patients diagnosed and followed up at the same institution during their whole course were considered. Secondly, to avoid possible biases, patients with post-polycythemic and post-thrombocythemic myelofibrosis were excluded from the study, since they can retain their propensity to thrombosis. Finally, patients with the so-called 'pre-fibrotic' form of myelofibrosis were also excluded, as they typically present with marked thrombocytosis. Therefore, the study group included a pure population of patients with 'classical' IM. In this homogeneous group of patients, the overall frequency of thrombosis was 11.6%, including the thromboses that occurred at disease presentation or shortly before. When compared with data from the general population, a significant increase in venous thrombosis was noted. The factors associated with the occurrence of thrombosis were thrombocytosis, cellular phase of myelofibrosis, presence of cardiovascular risk factors, and Hb 411 g/dl.
When only thrombotic events developing after IM diagnosis were considered, thrombosis probability was 9.6% at 5 years. As expected, this is lower than the figures for PV and ET. [1] [2] [3] [4] [5] At multivariate analysis, cellular phase of IM and presence of cardiovascular risk factors (arterial hypertension, smoking, hypercholesterolemia, and diabetes) were the independent predictors of thrombosis. In this sense, it must be pointed out that, although thrombocytosis did not retain its predictive value at multivariate level, most patients with thrombosis in whom such complication occurred before diagnosis or at presentation had high platelet counts and that, in our institution, the general policy was to administer platelet-lowering agents to patients with thrombocytosis. The importance of an adequate control of the cardiovascular risk factors to prevent the appearance of thrombosis does not need to be stressed. In this regard, the presence of high cholesterol levels in a minority of patients is of note, since low cholesterol levels are considered a marker of myeloproliferation. It could be therefore hypothesized that the presence of high cholesterol levels in a patient with IM could indicate even higher levels prior to diagnosis, with the myeloproliferation being not sufficient to normalize the cholesterol levels. According to this, high cholesterol levels would also be a cardiovascular risk factor in IM. As far as the cellular phase of IM is concerned, it is often associated with hyperproliferative features and there is current evidence of the role of blood cells in the pathogenesis of the thrombosis in the MPDs. 22, 23 In this regard, the recent identification of an acquired mutation in the JAK2 gene in most patients with PV and a half of those with ET or IM [24] [25] [26] [27] is of great importance, not only because it provides a rational basis for the use of targeted therapy, but also to investigate the possible relationship between the expression of the mutated gene and the risk of thrombosis in these patients.
In conclusion, the results herein reported provide for the first time reliable data on the frequency of major thrombosis in IM. As compared with the general population, a significant increase in venous thrombosis was found, with the main risk factors for the development of thrombosis being the hyperproliferative form of the disease and presence of cardiovascular risk factors. These observations should be taken into account to prevent thrombosis in patients with IM.
